Hypoadiponectinemia and Aldosterone Excess Are Associated with Lack of Blood Pressure Control in Subjects with Resistant Hypertension
Overview
Authors
Affiliations
Obesity, arterial stiffness and high aldosterone levels can interact to cause resistant hypertension (RHTN). Lower adiponectin (APN) levels may be significantly associated with hypertension. However, the importance of hypoadiponectinemia as a complicating factor in the lack of blood pressure (BP) control in individuals with RHTN has not been demonstrated. Ninety-six RHTN patients were classified into uncontrolled (UCRHTN, n = 44) and controlled (CRHTN, n = 52) subgroups. Their APN and aldosterone levels, office and ambulatory BP (ABPM) measurements, endothelium-dependent brachial artery responses (flow-mediated dilation (FMD)), left ventricular mass index (LVMI) and pulse wave velocity (PWV) were evaluated. The UCRHTN subgroup had increased aldosterone levels, as well as higher LVMI and PWV. In addition, lower APN levels and impaired FMD response were found in this subgroup. The brachial and ABPM pulse pressures were inversely associated with the APN levels (r = -0.45, P = 0.002; r = -0.33, P = 0.03, respectively), as were the aldosterone levels and the PWV (r = -0.38, P = 0.01; r = -0.36, P = 0.02, respectively) in UCRHTN patients. The PWV was only significantly influenced by the APN level in the UCRHTN subgroup in the multivariate regression analysis. None of the correlations mentioned above were observed in the CRHTN subgroup. Hypoadiponectinemia and high aldosterone levels may therefore be implicated in resistance to antihypertensive therapy related to arterial stiffness.
Negative Correlation of Serum Adiponectin Level with Aortic Stiffness in Elderly Diabetic Persons.
Hung J, Wu D, Chen M, Hsu B Int J Environ Res Public Health. 2022; 19(5).
PMID: 35270752 PMC: 8909958. DOI: 10.3390/ijerph19053062.
Takahashi Y, Yamazaki K, Kamatani Y, Kubo M, Matsuda K, Asai S Sci Rep. 2021; 11(1):19497.
PMID: 34593835 PMC: 8484335. DOI: 10.1038/s41598-021-98144-z.
Pro-inflammatory Cytokines and Resistant Hypertension: Potential for Novel Treatments?.
Pioli M, Faria A Curr Hypertens Rep. 2019; 21(12):95.
PMID: 31773311 DOI: 10.1007/s11906-019-1003-2.
Faria A, Ritter A, Gasparetti C, Correa N, Brunelli V, Almeida A Arq Bras Cardiol. 2019; 112(4):383-389.
PMID: 30843931 PMC: 6459424. DOI: 10.5935/abc.20190032.
Manolis A, Manolis T, Melita H, Manolis A Curr Hypertens Rep. 2019; 21(3):22.
PMID: 30826898 DOI: 10.1007/s11906-019-0924-0.